Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Suvorexant
Drug ID BADD_D02103
Description Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Indications and Usage Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Marketing Status approved; investigational
ATC Code N05CM19
DrugBank ID DB09034
KEGG ID D10082
MeSH ID C551624
PubChem ID 24965990
TTD Drug ID D00OVU
NDC Product Code 0006-0325; 0006-0001; 70966-0034; 0006-0003; 50473-0029; 0006-0002; 0006-0033; 0006-0004; 0006-0335; 0006-0005
UNII 081L192FO9
Synonyms suvorexant | (4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone | methanone, ((7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)- | MK 4305 | MK4305 | MK-4305 | Belsomra
Chemical Information
Molecular Formula C23H23ClN6O2
CAS Registry Number 1030377-33-3
SMILES CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mental disability26.01.01.001---
Middle insomnia17.15.03.003; 19.02.01.0030.002639%-
Migraine17.14.02.001; 24.03.05.0030.000575%-
Mood swings19.04.03.0010.000444%-
Movement disorder17.01.02.0100.000510%-
Muscle twitching15.05.03.0050.000444%-
Muscular weakness15.05.06.001; 17.05.03.0050.001241%
Musculoskeletal pain15.03.04.0070.000444%
Neck pain15.03.04.0090.000287%
Nervous system disorder17.02.10.0010.000287%-
Nervousness19.06.02.0030.000732%-
Nightmare19.02.03.0030.012269%-
Palpitations02.11.04.0120.001686%
Paralysis17.01.04.0040.000967%-
Paranoia19.05.01.0050.000287%-
Pemphigoid10.04.02.002; 23.03.01.0040.000131%-
Pollakiuria20.02.02.0070.001111%
Psychomotor hyperactivity17.01.02.011; 19.11.02.0030.000287%-
Respiratory depression17.02.05.047; 22.02.01.0100.000418%-
Restlessness17.02.05.021; 19.11.02.0020.001620%
Screaming08.01.03.099; 19.04.02.0200.000510%-
Sedation17.02.04.0050.000575%-
Sleep apnoea syndrome17.15.05.001; 19.02.05.002; 22.02.01.0130.000287%
Sleep disorder19.02.04.0010.006442%-
Sleep paralysis17.15.02.005; 19.02.02.0040.004639%-
Sleep terror17.15.02.006; 19.02.03.0080.001333%-
Sluggishness08.01.01.0040.000666%-
Somnambulism17.15.02.004; 19.02.03.0060.001842%-
Somnolence17.02.04.006; 19.02.05.0030.013393%
Speech disorder17.02.08.003; 19.19.02.002; 22.12.03.0270.000510%-
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages